ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2019年07月31日 08時00分
Source:
Eisai
エーザイ、E2082の臨床第I相試験（治験）における死亡例の発生について
東京, 2019年07月31日 - (JCN Newswire) - 当社が日本国内で実施していた健康成人を対象とした臨床第I相試験（治験）において、2019 年6 月に、1 名の被験者様が治験薬の投与を完了後にお亡くなりになりました。被験者様のご冥福をお祈り申し上げると共に、ご遺族様には謹んでお悔やみ申し上げます。
今回の治験で用いた治験薬は、神経系に作用する薬剤として当社が開発を進めておりました E2082です。
治験薬と被験者様の死亡の因果関係は不明であり、また、これまでに本治験において他の被験者様に重篤な副作用は報告されておりません。なお、E2082 の治験での投与は既にすべて中止しております。
当社は、速やかに厚生労働省に本事案を報告の上、同省の調査に積極的に協力しております。
当社は、被験者様がお亡くなりになったことを極めて重く受け止め、引き続き安全性に十分配慮し、高い倫理観を持って、医薬品の研究開発を行ってまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2019/pdf/news201958pdf.pdf
概要：エーザイ株式会社
詳細はwww.eisai.co.jpをご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Honda Presents World Premiere of Honda 0 Saloon and Honda 0 SUV Prototypes at CES 2025
Jan 08, 2025 17:32 JST
Honda and Renesas Sign Agreement to Develop High-Performance SoC for Software-Defined Vehicles
Jan 08, 2025 12:30 JST
Mitsubishi Motors to Display Custom Versions of the Triton at Tokyo Auto Salon 2025
Jan 07, 2025 15:41 JST
'Toyota Woven City,' a Test Course for Mobility, Completes Phase 1 Construction and Prepares for Launch
Jan 07, 2025 15:25 JST
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease
Jan 07, 2025 09:14 JST
Toyota to Share Progress on Woven City at CES 2025
Jan 06, 2025 15:49 JST
Mazda to build Module Pack Plant for Cylindrical Lithium-ion Batteries for Automotive Use in Iwakuni City, Yamaguchi Prefecture
Jan 06, 2025 15:36 JST
Galaxy Payroll Group Limited and People Intelligence Singapore Pte. Ltd. Announce Strategic Partnership
Jan 03, 2025 20:41 JST
Gruelling Challenge Awaits TGR In Saudi Arabia
Dec 27, 2024 15:20 JST
The General Incorporated Association Generative AI Japan Announces the Winners of the Japan Generative AI Award 2024
Dec 27, 2024 11:00 JST
MHI Included in "World Index" of Dow Jones Sustainability Index for Second Consecutive Year
Dec 27, 2024 09:36 JST
TOYOTA GAZOO Racing to Exhibit at Tokyo Auto Salon 2025
Dec 26, 2024 17:11 JST
JCB Launches Red Guahan Shopping Mall Shuttle Free Ride Promotion in Guam
Dec 26, 2024 12:00 JST
Mazda Production and Sales Results for November 2024
Dec 26, 2024 11:46 JST
MHI Conducts Nighttime and Long-Distance Highway Demonstration Testing of Unmanned Aerial Vehicle Currently Under Development
Dec 26, 2024 09:47 JST
Hitachi delivers a turnkey rail solution for Ho Chi Minh City's first urban railway Line 1 in Vietnam
Dec 24, 2024 13:19 JST
Nissan and Honda sign MOU to consider business integration
Dec 24, 2024 11:18 JST
Olympus Named to Dow Jones Sustainability World Index for the Fourth Consecutive Year
Dec 24, 2024 11:00 JST
GAC Honda Begins Operation of New Energy Vehicle (NEV) Production Factory in Guangzhou, China
Dec 24, 2024 10:23 JST
Sarawak Premier Makes Inaugural Visit to Mitsubishi Power's Takasago Hydrogen Park
Dec 24, 2024 10:10 JST
More Latest Release >>
Related Release
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease
1/7/2025 9:14:00 AM JST
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
12/23/2024 5:22:00 PM JST
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
12/11/2024 2:45:00 PM JST
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
12/5/2024 11:22:00 AM JST
LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
11/28/2024 4:26:00 PM JST
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
11/26/2024 3:50:00 PM JST
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
11/20/2024 11:51:00 AM JST
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
11/20/2024 10:24:00 AM JST
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
11/15/2024 5:33:00 PM JST
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
11/15/2024 2:31:00 PM JST
More Press release >>